Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ceritinib
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Ceritinib with Brentuximab Vedotin in Treating Patients with ALK-Positive Anaplastic Large Cell Lymphoma
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9522, NCI-2016-00396, NCT02729961
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLDK378A2205, NCI-2015-00957, NCT02336451
Ceritinib in Treating Patients with Relapsed or Refractory ALK-Positive Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00056623, NCI-2015-00732, NCT02343679
Ceritinib and Stereotactic Ablative Radiation Therapy in Treating Patients with ALK-Rearranged Metastatic Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 042015-076, NCI-2015-01632, NCT02513667
Ceritinib in Treating Patients with Activated Gastrointestinal Malignancies That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-0802, NCI-2016-00335, NCT02638909
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: CLDK378X2103, NCI-2013-00903, 2012-002074-31, NCT01742286
Ceritinib and Combination Chemotherapy in Treating Patients with Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 248813, NCI-2014-01766, NCT02227940
Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0890, NCI-2015-00062, NCT02321501
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2120C, NCI-2015-01651, NCT02393625
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLDK378A2103, NCI-2015-01439, 2014-003741-95, NCT02422589
Ceritinib in Treating Patients with Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 082014-029, NCI-2014-02360, NCT02289144
Start Over